Lyra Therapeutics Inc.
OTC
Real-time Data
01:30 PM
Day's Range
0.362252 wk Range
0.3001Key Statistics
Symbol
LYRA
Name
Lyra Therapeutics Inc.
Currency
USD
Exchange
OTC
High
0.51999998
Low
0.36219999
Open
‪0.4501‬
Last
‪0.5200‬
Market Cap
922.93K
Volume
11.77K
Average Volume
25.88K
Dividend Yield
‪0.00%‬
Change
-0.05
Percent Change
-8.76
Timestamp
2026-07-17
Close
0.51999998
Today Range Start
‪0.3622‬
Today Range End
‪0.5200‬
52 Week Range Start
‪0.3001‬
52 Week Range End
‪8.75‬
Type
Stocks
Country
United States
Compliance - LYRA - Lyra Therapeutics Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-19
Business Screen
NON_COMPLIANT
Financial Screen
NON_COMPLIANT
Compliant Revenue
‪4.00%‬
Non Compliant Revenue
‪96.00%‬
Questionable Revenue
‪0.00%‬
Securities To Market Cap Ratio
‪50.00%‬
Debt To Market Cap Ratio
‪1.20%‬
Historical Data - LYRA - Lyra Therapeutics Inc.
Historical Data
Market Cap - LYRA - Lyra Therapeutics Inc.
Market Cap
2026-07-17
922.93K
2026-07-16
1.01M
2026-07-15
927.19K
2026-07-14
749.26K
2026-07-13
851.94K
2026-07-10
957.37K
2026-07-09
958.34K
2026-07-08
905.18K
2026-07-07
1.06M
2026-07-06
1.05M
Profile - LYRA - Lyra Therapeutics Inc.
Profile
Mic Code
PINX
Sector
Healthcare
Industry
Biotechnology
Employees
27
Lyra Therapeutics Inc. is a biopharmaceutical company focusing on developing therapies for patients with ear, nose, and throat (ENT) diseases. The company's primary purpose is to address the unmet needs in the treatment of chronic rhinosinusitis (CRS) and related conditions by utilizing an innovative polymer-based platform, XTreo, which offers sustained delivery of medications directly to the affected area. This strategic approach aims to enhance treatment efficacy, reduce systemic side effects, and improve patient outcomes. Lyra's work primarily impacts the healthcare sector, particularly within the specialty pharmaceuticals industry. The significance of Lyra Therapeutics in the market lies in its potential to transform ENT disease management with novel, localized therapies that address the root cause of the ailment, positioning itself as a leader in the evolution of targeted, long-term ENT treatments.
Profile Details
Type
Common Stock
Ceo
Dr. Maria Palasis Ph.D.
Address
480 Arsenal Way
City
Watertown
State
MA
Zip
02472
Country
United States
Phone
617 393 4600
